Pub. Date : 2019 Nov 26
PMID : 31771617
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |
| 2 | Additionally, the DNMT3b silencing reduced the OCT4 expression in sorafenib-resistant Hep3B cells with or without IL-6 treatment. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |
| 3 | Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |
| 4 | Notably, targeting DNMT3b with nanaomycin A significantly increased the cell sensitivity to sorafenib, with a synergistic combination index (CI) in sorafenib-resistant Hep3B cells. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |
| 5 | CONCLUSIONS: The DNMT3b plays a critical role in the IL-6-mediated OCT4 expression and the drug sensitivity of sorafenib-resistant HCC. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |
| 6 | Findings from this study highlight the significance of IL-6-DNMT3b-mediated OCT4 expressions in future therapeutic target for patients expressing cancer stemness-related properties or sorafenib resistance in HCC. | Sorafenib | DNA methyltransferase 3 beta | Homo sapiens |